Supply of Medicine and Medical / Surgical equipments : Bivalent Poliomyelitis Vaccine Live 10\ndose vial (with a suitable dropper)\nBivalent Poliomyelitis Vaccine Live Oral\n(bOPV)10 dose vial Bivalent Poliomyelitis\nVaccine Live BP,EP or USP Liquid stabilized\npreparation of live attenuated poliomyelitis\nvirus of the Sabin strains type 1 and type 3.\nEach immunizing dose of vaccine should\ncontain not less than 10 6 TCID50 for type 1\nand 10 5.8 TCID50 for type 3 (should\nconform to the formulation of ratio of 10:6 for\nvaccine virus sero type 1 and 3\nrespectively). One immunizing dose should\nbe contained preferably in two drops.\ni.Offers should be only from vaccine\nsuppliers recommended by World Health\nOrganization (WHO) for bulk purchase for\nthe U.N. Agencies.\nii.The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of\nanalysis,lot release certificate issued by\nlaboratory accredited by National Control\nAuthority and Summary Protocol of vaccine\nproduction and quality control test data\nshould be submitted for protocol review.\niii.Each consignment should have a minimu\nm remaining shelf life of 75% at the time of r\neceiving the consignment at MSD.\niv.The vaccine should also comply with the\ngeneral requirements for vaccines in the\nBP,EP or USP.\nv.The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\nvi.Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack\nduring delivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\nvii.The vaccine should be protected from\nlight and should be stored at a temperature -\n20'C. etc .

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA Sri Lanka has Released a tender for Supply of Medicine and Medical / Surgical equipments : Bivalent Poliomyelitis Vaccine Live 10\ndose vial (with a suitable dropper)\nBivalent Poliomyelitis Vaccine Live Oral\n(bOPV)10 dose vial Bivalent Poliomyelitis\nVaccine Live BP,EP or USP Liquid stabilized\npreparation of live attenuated poliomyelitis\nvirus of the Sabin strains type 1 and type 3.\nEach immunizing dose of vaccine should\ncontain not less than 10 6 TCID50 for type 1\nand 10 5.8 TCID50 for type 3 (should\nconform to the formulation of ratio of 10:6 for\nvaccine virus sero type 1 and 3\nrespectively). One immunizing dose should\nbe contained preferably in two drops.\ni.Offers should be only from vaccine\nsuppliers recommended by World Health\nOrganization (WHO) for bulk purchase for\nthe U.N. Agencies.\nii.The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of\nanalysis,lot release certificate issued by\nlaboratory accredited by National Control\nAuthority and Summary Protocol of vaccine\nproduction and quality control test data\nshould be submitted for protocol review.\niii.Each consignment should have a minimu\nm remaining shelf life of 75% at the time of r\neceiving the consignment at MSD.\niv.The vaccine should also comply with the\ngeneral requirements for vaccines in the\nBP,EP or USP.\nv.The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\nvi.Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack\nduring delivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\nvii.The vaccine should be protected from\nlight and should be stored at a temperature -\n20'C. etc . in Pharmaceuticals. The tender was released on Mar 20, 2025.

Country - Sri Lanka

Summary - Supply of Medicine and Medical / Surgical equipments : Bivalent Poliomyelitis Vaccine Live 10\ndose vial (with a suitable dropper)\nBivalent Poliomyelitis Vaccine Live Oral\n(bOPV)10 dose vial Bivalent Poliomyelitis\nVaccine Live BP,EP or USP Liquid stabilized\npreparation of live attenuated poliomyelitis\nvirus of the Sabin strains type 1 and type 3.\nEach immunizing dose of vaccine should\ncontain not less than 10 6 TCID50 for type 1\nand 10 5.8 TCID50 for type 3 (should\nconform to the formulation of ratio of 10:6 for\nvaccine virus sero type 1 and 3\nrespectively). One immunizing dose should\nbe contained preferably in two drops.\ni.Offers should be only from vaccine\nsuppliers recommended by World Health\nOrganization (WHO) for bulk purchase for\nthe U.N. Agencies.\nii.The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of\nanalysis,lot release certificate issued by\nlaboratory accredited by National Control\nAuthority and Summary Protocol of vaccine\nproduction and quality control test data\nshould be submitted for protocol review.\niii.Each consignment should have a minimu\nm remaining shelf life of 75% at the time of r\neceiving the consignment at MSD.\niv.The vaccine should also comply with the\ngeneral requirements for vaccines in the\nBP,EP or USP.\nv.The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\nvi.Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack\nduring delivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\nvii.The vaccine should be protected from\nlight and should be stored at a temperature -\n20'C. etc .

Deadline - Apr 30, 2025

MT reference number - 105339255

Product classification - Pharmaceutical products